Eli Lilly reported a 47.7% increase in second-quarter 2026 revenue, driven mainly by volume growth from Mounjaro and Zepbound, while earnings per share exceeded estimates. The company raised its revenue guidance and pointed to a bullish pipeline that includes retatrutide and Foundeo as it broadens its incretin portfolio. Merck reported 5% revenue growth in the same quarter, presenting a contrasting performance.